Evaluating Dermatologists' Knowledge of and Attitudes Toward Janus Kinase Inhibitor Therapy for the Treatment of Alopecia Areata

July 2024 in “ Journal of the American Academy of Dermatology ”

Ambika Nohria, Deesha Desai, Alison Lee, Theodora K. Karagounis, Jerry Shapiro, Michael Garshick, Kristen I. Lo Sicco

Janus kinase inhibitors alopecia areata JAKi rheumatoid arthritis dermatologists

Studysummary Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on jaad.org →

Discuss this study in the Community →

Research cited in this study

2 / 2 results

research Treatment of Moderate-to-Severe Alopecia Areata in Patients Over the Age of 65 With Baricitinib

January 2024 in “Clinical and Experimental Dermatology”

In this study, baricitinib treatment over an average of 18.5 months resulted in a 72% reduction in alopecia severity scores among patients aged 65 or older, with mild adverse effects and no severe complications reported.

research Janus Kinase Inhibitors For Alopecia Areata

12 citations , June 2023 in “JAMA network open”

In this study of seven randomized clinical trials, JAK inhibitors were associated with improved hair regrowth outcomes in alopecia areata patients compared to placebo, with oral administration being more effective than external application, though longer trials are needed to confirm safety and effectiveness.